HALO · Halozyme Therapeutics
20 filings
HALO 10-K Annual Reports
Halozyme Therapeutics - 20 annual reports
HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 4, 2016
- 8-K · Jan 11, 2016
- 8-K · Jan 13, 2016
- 8-K · Jan 26, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 8-K · Mar 7, 2016
- 8-K · May 6, 2016
- 10-Q · May 9, 2016
- 8-K · May 9, 2016
- 8-K · Jun 8, 2016
- 8-K · Aug 9, 2016
- 10-Q · Aug 9, 2016
- 8-K · Sep 1, 2016
- 10-Q · Nov 7, 2016
- 8-K · Nov 7, 2016
- 8-K · Dec 19, 2016
- 8-K · Jan 5, 2017
- 8-K · Jan 9, 2017
- 8-K · Jan 10, 2017
- 8-K · Feb 28, 2017
- 10-K · Feb 28, 2017
- 8-K · May 5, 2017
- 10-Q · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 19, 2017
- 8-K · Jul 5, 2017
- 8-K · Aug 8, 2017
- 10-Q · Aug 8, 2017
- 8-K · Sep 29, 2017
- 10-Q · Nov 7, 2017
- 8-K · Nov 7, 2017
- 8-K · Jan 10, 2018
- 8-K · Jan 12, 2018
- 10-K · Feb 20, 2018
- 8-K · Feb 20, 2018
- 8-K · Mar 22, 2018
- 8-K · Apr 6, 2018
- 8-K · May 2, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 10-Q · Aug 7, 2018
- 8-K · Aug 7, 2018
- 8-K · Sep 5, 2018
- 8-K · Sep 10, 2018
- 8-K · Nov 6, 2018
- 10-Q · Nov 6, 2018
- 8-K · Nov 26, 2018
- 8-K · Dec 13, 2018
- 8-K · Jan 9, 2019
- 10-K · Feb 21, 2019
- 8-K · Feb 21, 2019
- 8-K · May 3, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · Jun 12, 2019
- 8-K · Aug 6, 2019
- 10-Q · Aug 6, 2019
- 8-K · Sep 4, 2019
- 8-K · Nov 5, 2019
- 8-K · Nov 12, 2019
- 10-Q · Nov 12, 2019
- 8-K/A · Nov 12, 2019
- 8-K · Nov 12, 2019
- 8-K · Nov 14, 2019
- 8-K · Nov 18, 2019
- 8-K · Jan 14, 2020
- 8-K · Jan 16, 2020
- 8-K · Feb 24, 2020
- 8-K · Feb 24, 2020
- 10-K · Feb 24, 2020
- 8-K · May 4, 2020
- 10-Q · May 11, 2020
- 8-K · May 11, 2020
- 8-K · Aug 10, 2020
- 10-Q · Aug 10, 2020
- 8-K · Nov 2, 2020
- 10-Q · Nov 2, 2020
- 8-K · Jan 11, 2021
- 8-K · Jan 13, 2021
- 10-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 25, 2021
- 8-K · Mar 1, 2021
- 8-K · May 3, 2021
- 8-K · May 5, 2021
- 8-K · May 7, 2021
- 8-K · May 10, 2021
- 10-Q · May 10, 2021
- 8-K · Aug 9, 2021
- 10-Q · Aug 9, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K/A · Nov 2, 2021
- 8-K · Dec 10, 2021
- 8-K · Dec 13, 2021
- 8-K · Dec 29, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 3, 2022
- 10-K · Feb 22, 2022
- 8-K · Feb 22, 2022
- 8-K · Mar 15, 2022
- 8-K · Mar 21, 2022
- 8-K · Apr 13, 2022
- 8-K · May 6, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 24, 2022
- 8-K/A · Aug 9, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Aug 15, 2022
- 8-K · Aug 16, 2022
- 8-K · Aug 18, 2022
- 8-K · Aug 19, 2022
- 8-K · Nov 8, 2022
- 10-Q · Nov 8, 2022
- 8-K · Jan 10, 2023
- 8-K · Feb 6, 2023
- 10-K · Feb 21, 2023
- 8-K · Feb 21, 2023
- 8-K · Feb 23, 2023
- 8-K · Mar 13, 2023
- 8-K · Mar 16, 2023
- 8-K · May 8, 2023
- 8-K · May 9, 2023
- 10-Q · May 9, 2023
- 10-Q · Aug 8, 2023
- 8-K · Aug 8, 2023
- 8-K · Sep 7, 2023
- 8-K · Nov 6, 2023
- 10-Q · Nov 6, 2023
- 8-K · Jan 17, 2024
- 10-K · Feb 20, 2024
- 8-K · Feb 20, 2024
- 8-K · Apr 26, 2024
- 10-Q · May 7, 2024
- 8-K · May 7, 2024
- 10-Q · Aug 6, 2024
- 8-K · Aug 6, 2024
- 10-Q · Oct 31, 2024
- 8-K · Oct 31, 2024
- 8-K · Jan 8, 2025
- 8-K · Feb 13, 2025
- 10-K · Feb 18, 2025
- 8-K · Feb 18, 2025
- 8-K · Mar 21, 2025
- 8-K · May 2, 2025
- 8-K · May 6, 2025
- 10-Q · May 6, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 1, 2025
- 8-K · Oct 3, 2025
- 8-K · Oct 6, 2025
- 8-K · Oct 14, 2025
- 10-Q · Nov 3, 2025
- 8-K · Nov 3, 2025
- 8-K · Nov 5, 2025
- 8-K · Nov 7, 2025
- 8-K · Nov 12, 2025
- 8-K · Nov 24, 2025
- 8-K · Dec 8, 2025
- 8-K · Dec 9, 2025
- 8-K · Jan 28, 2026
- 8-K · Feb 17, 2026
- 10-K · Feb 17, 2026
- 8-K · Mar 12, 2026
- 8-K · Apr 24, 2026
- 8-K · Apr 30, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · May 11, 2026
- 8-K · Jul 2, 2026
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026
- 8-K · Aug 18, 2026
- 8-K · Sep 16, 2026
- 8-K · Sep 18, 2026
- 8-K · Sep 22, 2026
- 8-K · Sep 30, 2026
- 10-Q · Nov 5, 2026
- 8-K · Nov 5, 2026
- 2025Feb 17, 2026
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2025
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,396.6 million for 2025, up from $1,015.3 million in 2024, driven primarily by royalties of $867.8 million (up from $571.0 million) and product sales, net of $376.4 million. Revenues under collaborative agreements were $152.3 million. Operating income fell to $469.0 million from $551.5 million, reflecting $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, a $48.7 million impairment of the ATRS-1902 intangible asset, and higher cost of sales and SG&A. Net income was $316.9 million, or $2.56 per diluted share, compared with $444.1 million, or $3.43, in 2024. Royalty growth was led by DARZALEX SC, VYVGART Hytrulo and Phesgo, and the company said ENHANZE remains its largest revenue driver. The company significantly expanded its balance sheet during the year. It acquired Elektrofi (later renamed Halozyme Hypercon, Inc.) for total consideration of $810.4 million and Surf Bio for $305.0 million, plus up to $100.0 million in contingent milestones. In November 2025 it issued $750.0 million of 0.00% Convertible Notes due 2031 and $750.0 million of 0.875% Convertible Notes due 2032, and used proceeds to repurchase portions of its 2027 and 2028 Convertible Notes. Total long-term debt carrying value was $2,142.6 million at year-end, against cash, cash equivalents and marketable securities of $142.8 million. Stockholders' equity fell to $48.8 million from $363.8 million, largely due to share repurchases and capped call purchases recorded in equity. Management states that current cash and marketable securities are sufficient for at least the next 12 months, and the $750.0 million revolving credit facility was undrawn at year-end. Key risks highlighted in the filing include dependence on partner performance and regulatory approvals, reliance on rHuPH20 supply from contract manufacturers, product liability exposure, a patent infringement lawsuit against Merck over MDASE technology, U.S. drug pricing and tariff policy, and the potential dilution and cash settlement obligations of the convertible notes.
- 2024Feb 18, 2025
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2024
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,015,324 thousand ($1.02 billion) for 2024, up from $829,253 thousand in 2023. Royalties were $570,991 thousand, product sales, net were $303,492 thousand, and revenues under collaborative agreements were $140,841 thousand. Net income rose to $444,091 thousand from $281,594 thousand, and diluted EPS was $3.43 versus $2.10. ENHANZE, the company's rHuPH20-based subcutaneous drug delivery technology, is the largest revenue driver, and the company has eleven collaborations with nine currently approved partner products. The balance sheet at December 31, 2024 showed cash, cash equivalents and marketable securities of $596.1 million, against consolidated debt carrying value of $1,505.8 million, including $805.0 million of 0.25% convertible notes due 2027 and $720.0 million of 1.00% convertible notes due 2028. Management states these resources are sufficient to fund operations for at least the next 12 months. During 2024 the company repurchased $250.0 million of stock under an accelerated share repurchase agreement, and it has $500.0 million remaining under a $750.0 million program authorized in February 2024. The filing highlights concentration and execution risks. Partner A accounted for 41% of 2024 total revenues and Partner B for 17%. Revenue growth was driven largely by milestone timing and royalty growth from partner products such as DARZALEX SC and Phesgo. Key risks include reliance on partners' regulatory approvals and commercialization, single-source bulk rHuPH20 manufacturing, and an FDA Complete Response Letter received by Janssen in December 2024 for SC amivantamab.
- 2023Feb 20, 2024
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2023
Halozyme Therapeutics, Inc. reported full-year 2023 total revenues of $829.3 million, up from $660.1 million in 2022, with net income of $281.6 million (diluted EPS $2.10) compared with $202.1 million in 2022. Royalties rose to $447.9 million from $360.5 million, driven by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and new device royalties from the Antares acquisition. Total product sales, net, increased to $300.9 million from $191.0 million, led by proprietary products (XYOSTED and Hylenex) and bulk rHuPH20 sales. Revenues under collaborative agreements declined to $80.5 million from $108.6 million, reflecting the timing of milestones. The company's balance sheet carries $1,499.2 million of net long-term debt, consisting of 2027 and 2028 Convertible Notes with total principal of $1,525.0 million, against cash, cash equivalents and marketable securities of $336.0 million. Management states these resources are sufficient to fund operations for at least the next 12 months. Stockholders' equity fell to $83.8 million from $169.8 million, largely due to $402.4 million of share repurchases in 2023. In February 2024, the board authorized a new $750.0 million capital return program. Key risks highlighted include dependence on partners' regulatory approvals and commercialization, reliance on rHuPH20 as the core technology underlying most ENHANZE revenues, single-source contract manufacturers for bulk rHuPH20, and the Alexion and Horizon collaboration terminations effective in 2024. Customer concentration is significant, with one partner accounting for 44% of 2023 total revenues.
- 2022Feb 21, 2023
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2022
Halozyme Therapeutics, Inc. describes itself as a biopharma technology platform company whose proprietary enzyme, rHuPH20, facilitates subcutaneous delivery of injected drugs and fluids through its ENHANZE technology, licensed to partners including Roche, Takeda, Janssen, argenx, BMS and others. In 2022 total revenues were $660.1 million, up from $443.3 million in 2021, driven by royalties of $360.5 million (versus $203.9 million) and product sales, net of $191.0 million (versus $104.2 million). Net income was $202.1 million, or $1.44 per diluted share, compared with $402.7 million in 2021, which included a $154.2 million income tax benefit from the release of a valuation allowance; 2022 included $46.8 million of income tax expense. The company acquired Antares Pharma, Inc. on May 24, 2022 for total purchase consideration of $1,045.7 million, adding auto-injector technology and the proprietary products XYOSTED, TLANDO and NOCDURNA. Antares represented 17% of 2022 total revenues and 9% of total assets. Operating cash flow was $240.1 million, and cash, cash equivalents and marketable securities totaled $362.8 million at year-end. Total indebtedness was $1,506.1 million net of debt discount, including convertible notes with aggregate principal of $1,538.5 million, and the company stated it expects its cash to fund operations for at least the next twelve months. Investors should weigh the company's heavy reliance on ENHANZE collaborations, the leverage added by the 2028 convertible notes and 2022 credit facility, a cash-settlement obligation on convertible conversions that could reduce working capital, and the company's ongoing share repurchase program, under which 8.4 million shares had been repurchased for $350.0 million through December 31, 2022.
- 2021Feb 22, 2022
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2021
Halozyme Therapeutics, Inc. is a biopharma technology platform company that licenses its rHuPH20 enzyme-based ENHANZE drug delivery technology to biopharmaceutical companies to convert IV drugs into subcutaneous formulations. For 2021, total revenues were $443.3 million, up from $267.6 million in 2020. Royalties rose to $203.9 million from $88.6 million, driven mainly by DARZALEX FASPRO sales by Janssen and Phesgo sales by Roche. Product sales, net were $104.2 million, and revenues under collaborative agreements were $135.2 million. Net income was $402.7 million, or $2.74 per diluted share, which includes a $154.2 million income tax benefit from the release of the valuation allowance on deferred tax assets. The filing states that Halozyme expects income tax expense to begin in 2022 at an estimated rate approximating statutory rates, which would significantly reduce net income. The balance sheet shows cash, cash equivalents and marketable securities of $740.9 million at December 31, 2021. Total convertible note principal was $895.9 million, comprising $90.9 million of 1.25% notes due 2024 (classified as current) and $805.0 million of 0.25% notes due 2027. In March 2021, the company completed an induced conversion of $369.1 million of the 2024 notes. The company repurchased $350.1 million of common stock in 2021 and completed its $550.0 million program in October 2021. In December 2021 it authorized a second program of up to $750.0 million over three years and entered an accelerated share repurchase of $150.0 million. A $75.0 million secured revolving credit facility with Bank of America was entered in December 2021 and was undrawn at year end. The filing describes a concentration of revenue and risk: Partner B accounted for 48% of 2021 total revenues and Partner A for 25%. Management states that cash and marketable securities are sufficient to fund operations for at least the next twelve months. Key risks noted include dependence on collaborators, COVID-19 disruption, reliance on third-party contract manufacturers for bulk rHuPH20, and the reclassification of the 2024 notes to a current liability.
- 2020Feb 23, 2021
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2020
Halozyme Therapeutics, Inc. reported total revenues of $267.6 million for 2020, up from $196.0 million in 2019, and net income of $129.1 million (basic EPS $0.95), compared with a net loss of $72.2 million in 2019. The improvement was driven mainly by $123.0 million of revenues under collaborative agreements, including $69.5 million of event-based development milestones, and by royalty revenue of $88.6 million, up from $69.9 million, mainly from sales of DARZALEX FASPRO by Janssen. Product sales, net declined to $56.0 million from $66.1 million, primarily because of a one-off large partner order for bulk rHuPH20 in 2019. Research and development expense fell to $34.2 million from $140.8 million as the company halted PEGPH20 development after the HALO-301 trial failed its primary endpoint and refocused on its ENHANZE platform and Hylenex. The balance sheet carries a significant near-term obligation. The 1.25% Convertible Senior Notes due 2024 ($460.0 million principal, $397.2 million net carrying amount) are classified as a current liability because the conditional conversion feature was triggered as of December 31, 2020. Cash, cash equivalents and marketable securities totaled $368.0 million, and working capital was $133.4 million. The company stated it believes current cash will fund operations for at least the next twelve months, and in January 2021 it notified noteholders it will settle the note principal in cash. The company also reported an accumulated deficit of $474.6 million and repurchased 6.5 million shares for $150.0 million in 2020 under a $550.0 million three-year capital return program. The filing describes Halozyme as a biopharma technology platform company that licenses its rHuPH20-based ENHANZE drug delivery technology to ten collaborations, with five marketed partnered products and Hylenex recombinant as its one proprietary marketed product. Dependence on collaborators, third-party contract manufacturers and regulatory approvals remain key risks identified in the filing.
- 2019Feb 24, 2020
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2019
Halozyme Therapeutics, Inc. reported a net loss of $72.2 million for 2019 on total revenues of $196.0 million, compared with a net loss of $80.3 million on $151.9 million of revenue in 2018. The year was dominated by the November 4, 2019 announcement that the HALO-301 Phase 3 study of PEGPH20 failed to reach its primary overall survival endpoint (11.2 vs. 11.5 median months). The company halted PEGPH20 development, closed its oncology operations and cut headcount by approximately 55%, or about 160 positions, to focus solely on its ENHANZE technology and Hylenex. It recorded $28.4 million of restructuring charges in the fourth quarter of 2019 and expects to become sustainably profitable beginning in the second quarter of 2020. Revenue mix shifted considerably. Revenues under collaborative agreements were $60.0 million, including $45.0 million from the argenx collaboration, and product sales, net, rose to $66.0 million from $28.2 million, driven mainly by bulk rHuPH20 sales to Janssen. Royalties declined to $69.9 million from $79.0 million. Customer concentration was high: Roche accounted for 40% of 2019 total revenues, argenx 23% and Janssen 18%. The balance sheet changed significantly. In November 2019 the company issued $460.0 million of 1.25% Convertible Senior Notes due 2024 and used $200.0 million of the net proceeds to repurchase shares, alongside a $550.0 million three-year capital return program. Cash, cash equivalents and marketable securities were $421.3 million at year-end, and management believes these resources will fund operations for at least the next twelve months. Stockholders' equity fell to $91.8 million from $248.9 million, and the Royalty-backed Loan is estimated to be repaid in the second quarter of 2020.
- 2018Feb 21, 2019
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2018
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies, built largely on its rHuPH20 enzyme platform. Its ENHANZE drug delivery technology is licensed to nine collaborations, and it has one marketed product, Hylenex recombinant. Its lead proprietary candidate, PEGPH20, is in a Phase 3 trial (HALO 109-301) in stage IV pancreatic ductal adenocarcinoma. In November 2018 the FDA agreed to change the primary endpoint of that trial to overall survival alone, and the company projects the 330 OS events needed for the final analysis will be reached between August and November 2019. Financially, total revenues fell to $151.9 million in 2018 from $316.6 million in 2017, and the company reported a net loss of $80.3 million, or $0.56 per share, compared with net income of $63.0 million in 2017. Revenue in 2018 was driven by royalties of $79.0 million and collaboration revenue of $44.6 million, down from $202.7 million in 2017, which included large upfront license fees. Operating cash flow was negative $49.5 million, and cash, cash equivalents and marketable securities totaled $354.5 million at year-end. Long-term debt is concentrated in the $150 million Royalty-backed Loan and a Loan Agreement with Oxford and SVB, and the company states its current cash should fund operations for at least the next twelve months. Investors should weigh the company's reliance on collaboration payments and royalties against its ongoing PEGPH20 spending, which research and development expenses of $150.3 million in 2018 reflect, and the pending outcome of the HALO-301 trial. The filing also notes that Roche and Baxalta are depleting inventory ahead of manufacturing transitions, which lowered bulk rHuPH20 sales in 2018.
- 2017Feb 20, 2018
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2017
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies, built on its rHuPH20 enzyme platform. Its ENHANZE Technology is licensed to eight collaborators, and its lead proprietary program is PEGPH20, which is in Phase 3 testing (HALO-301) in stage IV pancreatic ductal adenocarcinoma. In 2017 total revenues rose to $316.6 million from $146.7 million in 2016, and the company reported net income of $62.97 million, compared with a net loss of $103.0 million in 2016. Results were driven mainly by $202.7 million of revenues under collaborative agreements, including $101.4 million of license revenue from BMS and $40.0 million from Alexion, while royalties grew to $63.5 million and product sales, net, were $50.4 million. The filing also highlights setbacks in the PEGPH20 program. The SWOG S1313 all-comers trial was stopped after a higher rate of death was seen in the PEGPH20 arm, with median overall survival of 7.7 months versus 14.4 months in the modified FOLFIRINOX arm. Halozyme also reports an accumulated deficit of $522.4 million, and it discontinued development of HTI-1511. Cash, cash equivalents and marketable securities were $469.2 million at year-end 2017, and management believes this will fund operations for at least the next twelve months. Debt totals $202.4 million in present value, consisting of a $150 million Royalty-backed Loan and a $55.9 million Oxford/SVB term loan. The company expects Roche and Baxalta to deplete inventory in 2018, which will lower bulk rHuPH20 product sales that year. Adoption of ASC Topic 606 on January 1, 2018 is expected to have a material impact on reported financials, with license revenues on a pro forma basis of $198.4 million and royalty revenues of $68.9 million for 2017. For investors, the key tension is between a much stronger 2017 driven by one-time upfront license fees and the binary, high-risk outcome of the Phase 3 PEGPH20 trial.
- 2016Feb 28, 2017
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2016
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. Its business rests on two pillars: developing proprietary products, led by PEGPH20 in oncology, and licensing its rHuPH20 enzyme platform (ENHANZE Technology) to biopharmaceutical partners. Its approved product, Hylenex recombinant, is sold in the U.S. through a distributor. The company reported total revenues of $146,691 thousand for 2016, up from $135,057 thousand in 2015, while net loss widened to $103,023 thousand from $32,231 thousand. Royalty revenue rose to $50,984 thousand, and Roche accounted for 63% of total revenues in 2016. The central near-term event in the filing is the January 2017 topline announcement of combined Stage 1 and Stage 2 results for Study 109-202 of PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma. In the 84 HA-High patients, median progression-free survival was 9.2 months in the PEGPH20 arm versus 5.2 months in the control arm (HR 0.51, p=0.048). The overall study population's primary PFS endpoint was also met with statistical significance (6.0 vs. 5.3 months, p=0.048). The exploratory overall survival result was 11.5 vs. 8.5 months, and the filing notes that about 40% of patients in the PEGPH20 arm discontinued treatment at the time of a 2014 clinical hold. A Phase 3 study (109-301) is ongoing. Financially, the company ended 2016 with cash, cash equivalents and marketable securities of $204,981 thousand, up from $108,339 thousand, primarily due to a $150 million royalty-backed loan from January 2016 and a $55.0 million senior secured loan from June 2016. Stockholders' equity moved to a deficit of $(32,481) thousand from $42,999 thousand. The company states that current cash is sufficient to fund operations for at least the next twelve months, and it has accumulated net losses of approximately $585.3 million through December 31, 2016.
- 2015Feb 29, 2016
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2015
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies, built on its rHuPH20 enzyme platform (ENHANZE Technology) and its lead candidate PEGPH20, which is in Phase 2 and Phase 3 testing for stage IV pancreatic ductal adenocarcinoma. Revenue rose to $135.1 million in 2015 from $75.3 million in 2014, driven by $58.0 million in revenues under collaborative agreements (including $25.0 million from Lilly and $23.0 million from AbbVie license fees) and $31.0 million in royalties. Net loss narrowed to $32.2 million, or $0.25 per share, from $68.4 million, while the company has never been profitable and had an accumulated deficit of $482.7 million at year-end. Research and development expense rose to $93.2 million, with PEGPH20 program expense increasing to $75.6 million from $34.9 million, reflecting expanded clinical activity. Cash, cash equivalents and marketable securities were $108.3 million at December 31, 2015, which the company says will fund operations for at least the next twelve months. Subsequent to year-end, in January 2016, Halozyme Royalty received a $150 million royalty-backed loan secured by royalties from the Roche and Baxalta collaborations, and the company expects cash to increase by approximately $35 million to $55 million in 2016. Key risks include the April 2014 clinical hold on Study 109-202 related to thromboembolic (TE) event rates, which the company says could be halted again if FDA finds safety imbalances; the company's reliance on contract manufacturers and a single collaborator concentration (Roche represented 42% of 2015 revenues); and the need to raise additional capital in the future. The Phase 3 Study 109-301 began in the first quarter of 2016, with a companion diagnostic being developed with Ventana.
- 2014Mar 2, 2015
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2014
Halozyme Therapeutics, Inc. (filed as Halozyme Therapeutics; ticker HALO) reported total revenues of $75.3 million for 2014, up from $54.8 million in 2013, and a net loss of $68.4 million, or $0.56 per share, compared with a net loss of $83.5 million in 2013. Product sales, net rose to $37.8 million, revenues under collaborative agreements were $28.1 million (including a $15.0 million license fee from the Janssen Collaboration), and royalties were $9.4 million. Roche accounted for 57% of 2014 total revenues. Accumulated deficit reached $450.4 million at December 31, 2014. Management reported cash, cash equivalents and marketable securities of $135.6 million and said this is sufficient to fund operations for at least the next twelve months, with anticipated 2015 net cash burn of $35 million to $45 million. The company has refocused its strategy on PEGPH20, an investigational PEGylated hyaluronidase for tumors that accumulate hyaluronic acid, with its lead trial in metastatic pancreatic cancer (Study 109-202) in Phase 2. That trial was placed on clinical hold in April 2014 over a possible difference in thromboembolic event rates and resumed in July 2014 under a revised protocol. PEGPH20 received FDA Fast Track and Orphan Drug designations. Halozyme plans to pursue collaborations or other strategic alternatives for its diabetes and dermatology programs, and it reduced its workforce by approximately 13% in November 2014. Enhanze collaborations with Roche, Baxter, Pfizer and Janssen remain the other core revenue driver, with one product approved in the U.S. and three in Europe. Key risks for investors include dependence on the PEGPH20 program and its thromboembolic safety profile, reliance on a small number of collaborators and contract manufacturers, uncertainty over FDA labeling requirements for Hylenex recombinant in insulin pump use, a $50 million term loan secured by substantially all assets, and a history of losses with no profitability to date.
- 2013Feb 28, 2014
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2013
Halozyme Therapeutics, Inc. is a science-driven biopharmaceutical company focused on human enzymes that alter the extracellular matrix, with its core technology built on rHuPH20, a recombinant human hyaluronidase. Its only marketed proprietary product is Hylenex recombinant, and its value depends heavily on collaborations with Roche, Pfizer, Baxter and Intrexon. For 2013, total revenues were $54.8 million (versus $42.3 million in 2012), driven by product sales of $24.4 million and revenues under collaborative agreements of $30.4 million. The company reported a net loss of $83.5 million ($0.74 per share), up from $53.6 million in 2012, and an accumulated deficit of $382.1 million as of December 31, 2013. The balance sheet weakened over the year. Cash, cash equivalents and marketable securities fell to $71.5 million from $99.5 million, and stockholders' deficit was $20.0 million compared with equity of $48.9 million a year earlier. Long-term debt rose to $49.8 million after the December 2013 amended loan agreement increased the term loan to $50 million, maturing January 1, 2018. Management stated that existing cash is sufficient for at least the next twelve months, excluding the February 2014 offering, and it anticipates net cash burn of approximately $45 to $55 million for 2014. The company completed an underwritten offering of 8,846,153 shares at $13.00 per share in February 2014, generating about $107.8 million in net proceeds. Key 2014 catalysts include top-line CONSISTENT 1 results for the ultrafast insulin program expected in the first quarter, HTI-501 data at three and six months, and PEGPH20 Phase 2 enrollment expected to complete in the second half. Risks flagged in the filing include FDA questions about non-neutralizing anti-rHuPH20 antibodies that led to a complete response letter for Baxter's HyQvia, the termination of the ViroPharma collaboration in February 2014, and dependence on contract manufacturers Avid and Cook.
- 2012Mar 1, 2013
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2012
Halozyme Therapeutics, Inc. reported total revenues of $42.3 million for 2012, down from $56.1 million in 2011, and a net loss of $53.6 million, compared with $19.8 million in 2011. Revenues under collaborative agreements were $39.4 million, including $9.5 million recognized from the Pfizer Collaboration signed in December 2012. Product sales of Hylenex recombinant were $2.9 million. Research and development expense rose to $70.0 million and selling, general and administrative expense to $24.8 million. The company has never been profitable and reports an accumulated deficit of approximately $298.6 million as of December 31, 2012. At year-end 2012, Halozyme had cash and cash equivalents of $99.9 million, versus $52.8 million a year earlier. The increase reflects an $81.5 million net proceeds public offering in February 2012 and a $30 million secured term loan drawn in December 2012 (net proceeds of $29.7 million). The company expects total net cash burn of approximately $45 to $50 million for 2013 and states that its current cash is sufficient to fund operations for at least the next twelve months. It does not expect revenues to fund operations until 2014 at the earliest. The key risk in the filing is the rHuPH20 enzyme platform. In August 2012 the FDA issued a complete response letter for Baxter's HyQ biologics license application, citing non-neutralizing antibodies to rHuPH20, and the FDA asked that patients no longer be dosed with rHuPH20 in the Baxter HyQ program. ViroPharma's subcutaneous Cinryze program was placed on temporary clinical hold and later allowed to resume. Halozyme believes the HyQ issues will not significantly affect its proprietary and other collaboration candidates, but it cannot provide assurance of that outcome. Only three collaboration product candidates are in the regulatory approval process, and no proprietary candidates are.
- 2011Mar 12, 2012
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2011
Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on human enzymes that alter the extracellular matrix. Its lead enzyme, rHuPH20, underpins its Enhanze drug delivery technology, its Hylenex recombinant product, and its proprietary pipeline, including an ultrafast insulin program (Analog-PH20), PEGPH20 for solid tumors, and HTI-501 for cellulite. The company reported total revenues of $56.1 million for 2011, up from $13.6 million in 2010, driven primarily by $18.0 million in upfront license fees from the ViroPharma and Intrexon partnerships and $18.1 million of deferred revenue recognized upon the termination of the Hylenex Partnership with Baxter. Net loss narrowed to $19.8 million, or $0.19 per share, from $53.2 million, or $0.56 per share, in 2010. Accumulated deficit stood at approximately $245.0 million at December 31, 2011. Cash and cash equivalents were $52.8 million at year-end 2011, and the company expects net cash burn of approximately $50.0 to $55.0 million for 2012. Subsequent to year-end, on February 15, 2012, Halozyme sold approximately 7.8 million shares at $10.61 per share, generating approximately $81.8 million in net proceeds before expenses, and management states current cash is sufficient for at least the next twelve months. Hylenex recombinant was reintroduced to the U.S. market in December 2011 after a May 2010 voluntary recall, and the company now sells it through a distributor while Baxter fills and finishes product under a contract that initially runs through December 2012. The company relies heavily on partner milestones and royalties, with Roche (19%), Baxter (42%), ViroPharma (22%) and Intrexon (16%) accounting for total 2011 revenues as stated in the filing. The filing also highlights dependence on a small number of contract API manufacturers, the absence of any product currently in a proprietary regulatory approval process, and a history of net losses with no profitability to date.
- 2010Mar 11, 2011
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2010
Halozyme Therapeutics, Inc. reported total revenues of $13,624,115 for 2010, compared with $13,671,305 in 2009, while its net loss narrowed to $53,241,650 ($0.56 per share) from $58,360,523 ($0.67 per share). Product sales were $895,518 and revenues under collaborative agreements were $12,728,597. Research and development expense was $51,773,504 and selling, general and administrative expense was $15,122,960. The company has never been profitable and reported an accumulated deficit of $225,251,795 at December 31, 2010. The filing describes a year of significant setbacks and restructuring. HYLENEX was voluntarily recalled in May 2010 because a portion manufactured by Baxter did not comply with agreement requirements. In January 2011, Halozyme and Baxter agreed to terminate the HYLENEX Partnership, and Halozyme reacquired worldwide HYLENEX marketing rights. The company says it expects to reintroduce HYLENEX in the second half of 2011, subject to FDA review. In October 2010, a reorganization cut the workforce by approximately 25 percent, and Jonathan E. Lim, M.D. resigned as CEO in December 2010, with Gregory I. Frost, Ph.D. succeeding him. The company's pipeline centers on its rHuPH20 enzyme, with its lead proprietary program being an ultrafast insulin program and a PEGylated version, PEGPH20, in Phase 1 testing for solid tumors. Partnered programs include Roche's subcutaneous Herceptin and MabThera, which are in Phase 3, and Baxter's GAMMAGARD LIQUID. Management states that cash and cash equivalents of $83,255,848 are sufficient to fund operations for at least the next twelve months, and it anticipates net cash burn of approximately $47.0 to $52.0 million for 2011.
- 2009Mar 12, 2010
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2009
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $13,671,305 for 2009, up from $8,764,139 in 2008, while its net loss widened to $58,360,523 ($0.67 per share) from $48,654,199 ($0.61 per share). Revenues under collaborative agreements were $12,700,458, and product sales were $970,847. Research and development expenses rose to $56,614,266 from $44,232,936, driven mainly by the ultrafast insulin and PEGPH20 programs. The company has never been profitable and had an accumulated deficit of $172,010,145 at December 31, 2009. The company's business centers on rHuPH20, a recombinant human hyaluronidase enzyme that underpins its Enhanze Technology drug delivery platform and its proprietary programs. Partnerships with F. Hoffmann-La Roche and Baxter Healthcare are the core of its revenue base, and Roche's Phase 3 subcutaneous Herceptin trial began in October 2009. HYLENEX and Cumulase are its two marketed products, and product sales remain very limited. Cash and cash equivalents were $67,464,506 at year-end, and management stated that current cash is sufficient to fund operations for at least the next twelve months, with anticipated 2010 net cash burn of approximately $40.0 to $45.0 million. Investors should note that stockholders' equity fell to $6,903,389 from $15,379,996, and that the company expects to raise additional capital, potentially through a universal shelf registration of up to $100.0 million filed in January 2010. The filing also discloses dependence on third-party manufacturers (Avid Bioservices and Cook Pharmica) and partners for product supply and commercialization.
- 2008Mar 13, 2009
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2008
Halozyme Therapeutics, Inc. (filed under this name; now trading on NASDAQ as HALO) reported its annual results for fiscal 2008 in this Form 10-K, filed March 13, 2009. The company is a biopharmaceutical company focused on products targeting the extracellular matrix, built on its recombinant human PH20 hyaluronidase enzyme (rHuPH20). Total revenues were $8,764,139 in 2008, up from $3,799,521 in 2007, but net loss widened to $48,654,199 ($0.61 per share) from $23,896,183 ($0.32 per share), driven by research and development expense rising to $44,232,936 from $20,554,105. The company has never been profitable, with an accumulated deficit of $113.6 million as of December 31, 2008. At year-end 2008, cash and cash equivalents were $63,715,906, down from $97,679,085, and stockholders' equity fell to $15,379,996 from $57,767,924. Management believes current cash will fund operations for at least the next twelve months and expects net cash burn of approximately $30.0 to $35.0 million for 2009. The company's revenue depends heavily on partners: Baxter accounted for 51% and Roche for 44% of 2008 total revenues. Management stated that Baxter's sales and marketing resources for HYLENEX have not met its expectations, and the company decided in early 2009 to reallocate resources away from its Chemophase bladder cancer program. Key pipeline items include a Phase II trial of rHuPH20 combined with insulin in Type 1 diabetic patients (started November 2008), a first Phase I trial of PEGPH20 in advanced solid tumors, and a Phase III trial of GAMMAGARD LIQUID with rHuPH20 announced for January 2009. The company also disclosed a universal shelf registration of up to $50.0 million and approximately 1.9 million warrants outstanding that expire in October 2009.
- 2007Mar 14, 2008
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2007
Halozyme Therapeutics, Inc. (filed under this name; now HALO on NASDAQ) reported total revenues of $3,799,521 for fiscal 2007, up from $981,746 in 2006, while net loss widened to $23,896,183 ($0.32 per share) from $14,751,986 ($0.24 per share). Revenue under collaborative agreements was $3,159,931 and product sales were $639,590. Research and development expense rose to $20,554,105 from $9,214,759, and selling, general and administrative expense rose to $11,155,194 from $6,912,853, reflecting outsourced pre-clinical work, rHuPH20 manufacturing scale-up, and headcount growth. The company stated its accumulated deficit was approximately $65.0 million at December 31, 2007, and that it has never been profitable. Cash and cash equivalents increased to $97,679,085 at year-end 2007 from $44,189,403, driven by financing of $56,002,668, including approximately $32.1 million from a sale of common stock to New River Management V, LP, approximately $20.0 million from an affiliate of Baxter, and $21.0 million of initial upfront payments from Baxter. Deferred revenue rose to $39,269,491. The company stated its current cash should be sufficient for at least the next twelve months and anticipated 2008 cash expenses of approximately $40 million to $50 million. It also disclosed warrants to purchase about 4.9 million shares outstanding, with a universal shelf registration allowing up to $32.5 million of additional securities. The business rests on its recombinant human PH20 hyaluronidase (rHuPH20) platform. Hylenex and Cumulase are marketed products, and Chemophase, its lead oncology candidate, is in Phase I/IIa. Partnerships with Roche (up to thirteen targets, $20 million upfront) and Baxter (Enhanze and Gammagard agreements) are central to its revenue outlook. The filing identifies heavy dependence on a single contract manufacturer (Avid Bioservices) and on Baxter for Hylenex distribution and fill-finish as key risks.
- 2006Mar 9, 2007
Halozyme Therapeutics Annual Report, Year Ended Dec 31, 2006
Halozyme Therapeutics, Inc. (filed under the name shown in the filing) is a biopharmaceutical company developing and commercializing recombinant human enzymes for drug delivery, palliative care, oncology, and infertility. Its technology is based on recombinant human PH20 (rHuPH20), a human synthetic version of hyaluronidase. In fiscal 2006 the company had total revenues of $981,746 against total expenses of $16,564,602, resulting in a net loss of $14,751,986, or $0.24 per share. Accumulated deficit stood at $41,099,240 as of December 31, 2006, and the company has never been profitable. Cash and cash equivalents rose to $44.2 million at year-end 2006, which the filing attributes primarily to a $20.0 million upfront payment from Roche and $11.0 million from a common stock sale to a Roche affiliate, plus $7.3 million from warrant and option exercises. The company states that its current cash will be sufficient to fund operations for at least the next twelve months. The company's commercial position is still early. Cumulase, its IVF product, and Hylenex, approved by the FDA in December 2005, generated limited revenue, with Cumulase product sales of $342,000 and Hylenex API sales of $329,000 in 2006. In December 2006, Roche licensed Enhanze Technology for up to thirteen targets, with up to $111 million in potential milestones on the first three targets. In February 2007, Baxter amended its Hylenex agreements, paid a $10 million upfront payment, and may make milestone payments of up to $25 million, while Baxter will now assume development, manufacturing, and marketing costs for the covered products. Chemophase, the lead oncology candidate, is in a Phase I/IIa trial for superficial bladder cancer. Key risks highlighted in the filing include dependence on a sole contract manufacturer (Avid Bioservices) and a single fill-and-finish partner for Hylenex, competition from animal-derived hyaluronidase products, the possibility that the company will need to raise additional capital, and the dilutive effect of about 6.4 million outstanding warrants.